Business Wire

CA-NEXON-AMERICA

16.1.2023 15:02:40 CET | Business Wire | Press release

Share
Star Guardian Sia Astelle Arrives in MapleStory M as the First, All-new Exclusive Character!

Last week, free-to-play mobile MMORPG MapleStory M from Nexon, brought the heavens down to Maple World with the release of its first original character, Sia Astelle. This brand-new Star Guardian (Magician class) has never been seen in other global versions of MapleStory, nor has the character been available in other versions of MapleStory M before!

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005080/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Nexon America proudly introduces Sia Astelle, the first brand new, original character in MapleStory M. (Graphic: Business Wire)

Sia Astelle is the guardian of Oort, the home to the celestial order of stars. Her first duty is in service to the cosmos, guiding stars along their destined path. After a series of strange events occur, Sia arrives in Maple World when she is forced to leave her tranquil life on Oort behind.

In addition to the new Star Guardian character, MapleStory M’s latest update boasts a wide array of improvements and events to start the new year right, including max EXP stat increase from 250% to 300%, improvements to MapleStory M's end game gear Necro equipment, skill presets, and more.

Also, while playing as Sia Astelle, mobile Maplers can benefit from bonus rewards and events:

  • Pre-creation reward (1/11 after maintenance until 1/25) A reward for players who participated in ‘Sia Astelle Pre-Creation event’.
  • Growth mission event (1/11 after maintenance until 2/12) - Rewards available for Sia after reaching a certain level and completing certain missions.
  • Mega Burning Plus event (1/11 after maintenance until 2/12) - Sia will earn an additional 2 levels every time the character levels up.
  • Grow with Sia Astelle event (1/11 after maintenance until 2/12) - Rewards and EXP will be granted to another selected character player when Sia levels up.

Other celebratory events help ring in the new year in Maple World:

  • New Year event: “I Just Wanted to Have a Fulfilling Year, but Being Hero Is Too Much!” (1/11 until 2/22) - A series of multiple mini-game events where players need to save the world by participating in various tasks such as delivering food, collecting coins while hunting, and climbing trees to avoid obstacles. Maplers can also take down Lord Pixrog in a boss battle and receive rewards based on the participation count.
  • 2023 Happy New Year! event (1/18 until 2/1) - Players can open lucky red envelopes with 2023 Special Energy acquired through hunting.
  • 2023 Lunar New Year 14-day Login event (1/18 until 2/8) - Players can log into MapleStory M for 14 consecutive days to earn rewards!

Visit the world of MapleStory M and experience the cosmic wonder of Sia Astelle! To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.

Assets: Image

Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord

About MapleStory M https://maplestorym.nexon.com/

MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines, and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and celebrates its four-year anniversary in 2022 having 16 million total downloads globally.

About Nexon America Inc. https://www.nexon.com/

Founded in 2006, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005080/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye